inclusion criteria: * age 50 years and older or 18-49 with 1 or more chronic high-risk medical conditions, and/or immunosuppression: chronic respiratory disease (including copd, cystic fibrosis and asthma requiring at least daily use of preventative and/or reliever medication); chronic heart or vascular disease; chronic kidney disease; chronic liver disease; chronic neurological disease (including dementia, stroke, epilepsy); severe and profound learning disability; down's syndrome; diabetes (type 1 or type 2); immunosuppression: primary (e.g. inherited immune disorders resulting from genetic mutations) or secondary due to disease or treatment (e.g. sickle cell, hiv, cancer, chemotherapy); solid organ, bone marrow and stem cell transplant recipients; morbid obesity (bmi \>35); severe mental illness; care home resident. * confirmed sars-cov-2 by nucleic acid testing or rapid antigen testing with proof of a positive test provided via a picture of the result * able to be enrolled and begin the study therapeutic within 5 days of onset of symptoms associated with sars-cov-2 infection

inclusion criteria: * age 50 years and older or 18-49 with 1 or more chronic high-risk medical conditions, and/or immunosuppression: chronic respiratory disease (including copd, cystic fibrosis and asthma requiring at least daily use of preventative and/or reliever medication); chronic heart or vascular disease; chronic kidney disease; chronic liver disease; chronic neurological disease (including dementia, stroke, epilepsy); severe and profound learning disability; down's syndrome; diabetes (type 1 or type 2); immunosuppression: primary (e.g. inherited immune disorders resulting from genetic mutations) or secondary due to disease or treatment (e.g. sickle cell, hiv, cancer, chemotherapy); solid organ, bone marrow and stem cell transplant recipients; morbid obesity (bmi \>35); severe mental illness; care home resident. * confirmed sars-cov-2 by nucleic acid testing or rapid antigen testing with proof of a positive test provided via a picture of the result * able to be enrolled and begin the study therapeutic within 5 days of onset of symptoms associated with sars-cov-2 infection

inclusion criteria: age 50 years and older or 18-49 with 1 or more chronic high-risk medical conditions, and/or immunosuppression: chronic respiratory disease (including copd, cystic fibrosis and asthma requiring at least daily use of preventative and/or reliever medication); chronic heart or vascular disease; chronic kidney disease; chronic liver disease; chronic neurological disease (including dementia, stroke, epilepsy); severe and profound learning disability; down's syndrome; diabetes (type 1 or type 2); immunosuppression: primary (e.g. inherited immune disorders resulting from genetic mutations) or secondary due to disease or treatment (e.g. sickle cell, hiv, cancer, chemotherapy); solid organ, bone marrow and stem cell transplant recipients; morbid obesity (bmi >35); severe mental illness; care home resident. confirmed sars-cov-2 by nucleic acid testing or rapid antigen testing with proof of a positive test provided via a picture of the result able to be enrolled and begin the study therapeutic within 5 days of onset of symptoms associated with sars-cov-2 infection

inclusion criteria: age 50 years and older or 18-49 with 1 or more chronic high-risk medical conditions, and/or immunosuppression: chronic respiratory disease (including copd, cystic fibrosis and asthma requiring at least daily use of preventative and/or reliever medication); chronic heart or vascular disease; chronic kidney disease; chronic liver disease; chronic neurological disease (including dementia, stroke, epilepsy); severe and profound learning disability; down's syndrome; diabetes (type 1 or type 2); immunosuppression: primary (e.g. inherited immune disorders resulting from genetic mutations) or secondary due to disease or treatment (e.g. sickle cell, hiv, cancer, chemotherapy); solid organ, bone marrow and stem cell transplant recipients; morbid obesity (bmi >35); severe mental illness; care home resident. confirmed sars-cov-2 by nucleic acid testing or rapid antigen testing with proof of a positive test provided via a picture of the result able to be enrolled and begin the study therapeutic within 5 days of onset of symptoms associated with sars-cov-2 infection